Skip to main content
Premium Trial:

Request an Annual Quote

Vitalea, Accium Collaborate to Cross-validate AMS Platform

NEW YORK (GenomeWeb News) – Bioanalytical contract services firms Vitalea Sciences and Accium BioSciences today announced an agreement to cross-validate each other's' accelerator mass spectrometry platform.

The companies said successful completion of the studies "will permit delivery of bioanalytical services supported by backup AMS instrumentation operating under a unified and validated framework."

Financial and other terms of the deal were not disclosed.

AMS complements other tools for bioanalytical research and can be used to quantify the pharmacokinetics and metabolism of drug candidates prior to or as part of Phase 1 clinical trials.

Bob Bethem, CEO of Vitalea, based in Davis, Calif., said in a statement that his company and Accium will continue to compete for AMS studies, "but our labs share a common guiding principle to share our AMS services according to industry expectations. We will continue to provide the highest level of study design and execution at Vitalea with the added reassurance of this new backup contingency plan."

Ali Arjomand, president and COO of Seattle-based Accium, added, "The cooperative agreement announced here will bridge the AMS resources and technical expertise of both companies and provide greater value to pharmaceutical sponsors and the AMS community at large."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.